Navigation Links
Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
Date:12/14/2007

SUNNYVALE, Calif., Dec. 14 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that its Pathwork(R) Tissue of Origin Test is the focus of a study published in the January issue of The Journal of Molecular Diagnostics. Pathwork's genomics-based test is designed to help determine a tumor's origin so that tissue-specific management can begin. The study, performed by principal investigator Federico A. Monzon, M.D., and colleagues from the University of Pittsburgh, Virginia Commonwealth University and Stanford University, examined the analytical performance characteristics and reproducibility of the Tissue of Origin Test.

There are an estimated 200,000 cancer patients with an uncertain primary diagnosis on their cancers each year in the U.S.(1),(2),(3) These people may benefit from additional diagnostic information to determine the tissue of origin for their cancer. One study showed that, in such cases, the primary tumor site is identified only 25 percent of the time using traditional diagnostic tools. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the tissue of origin so that management specific to the primary cancer can begin.

The Pathwork Tissue of Origin Test measures the expression of more than 1600 genes and compares a tumor's gene expression "signature" against those of 15 known tissue types. The test uses microarray technology, which enables large numbers of genes to be evaluated at the same time, using the proven, commercially available Affymetrix microarray platform.

In the study, 60 archived tissue specimens from poorly and undifferentiated tumors (metastatic and primary) were analyzed at four laboratories representing a wide range of pre-analytical conditions. Reproducibility was analyzed by cross-wise comparisons of all 4 sites. Cross-laboratory comparisons, performed using a variety of measures, showed highly reproducible results between laboratories. Overall concordance between laboratories in terms of final tissue of origin calls was 93.8%.

"As a result of the study, we concluded that the Pathwork Tissue of Origin Test is a robust assay that produces consistent results in diverse laboratory conditions reflecting the pre-analytical variations found in the everyday clinical practice of molecular diagnostics laboratories," explained Catherine I. Dumur, Ph.D., of Virginia Commonwealth University, lead author of the manuscript.

"This test has the potential to be an effective aid in the diagnosis of cancer patients presenting with poorly differentiated and undifferentiated tumors," commented Dr. Monzon, now at The Methodist Hospital in Houston, TX.

Note: The Pathwork Tissue of Origin Test is not cleared by the FDA for sale in the U.S. It is for Investigational Use Only.

About Pathwork Diagnostics

Pathwork Diagnostics, based in Sunnyvale, California, develops and delivers genomics-based diagnostics that advance cancer care. The company solves unmet clinical needs in oncology by using innovative technology to harness the power of genomics information and apply it in a robust, reproducible and reliable manner. Pathwork Diagnostics plans to deliver FDA-cleared microarray-based diagnostic tests for oncology to the clinical laboratory. The company's initial tests will consist of Pathwork Diagnostics' proprietary analytics and a companion Pathchip(TM) microarray, which runs on the proven Affymetrix instrument system. The company's first test -- the Pathwork(R) Tissue of Origin Test -- is designed to be an aid in the diagnosis of the tissue of origin in patients with poorly or undifferentiated tumors or metastases.

(1) Pavlidis, Fizazi. Cancer of unknown primary. Critical Reviews in

Oncology Hematology 54 (2005) 243-50.

(2) Tong et al. Incidence, costs of care and survival of Medicare

beneficiaries diagnosed with carcinoma of unknown primary. Abstract

presented at ASCO 2006.

(3) Pathwork Diagnostics analysis.


'/>"/>
SOURCE Pathwork Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... SAN FRANCISCO , April 27, 2016 /PRNewswire/ ...  is expected to reach USD 2.06 billion by ... View Research, Inc. Increasing consumer awareness towards a ... over the next seven years.      ... Improper diet intake coupled with rising health treatment ...
(Date:4/26/2016)... Mich. , April 26, 2016 Diplomat ... promotion of Jennifer Hagerman , Pharm D., to ... her growing role at Diplomat, Hagerman will continue to ... the company that delivers custom education and training to ... the specialty pharmacy industry. Diplomat University also houses the ...
(Date:4/26/2016)... 2016 US demand for infection prevention ... percent annually to $27.6 billion in 2020.  Increasing ... decrease rates of healthcare-associated infections (HAIs) will boost ... services.  Although declining, the overall rate of certain ... set by the CDC.  Recent statistics indicate that ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Mercy College is expanding its Graduate Business Programs to the ... due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership (MSOL) ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe that ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded ... to confront and deal with these stressors is to adopt a more healthful diet, ... for you. Risa Groux, a certified Holistic Nutritionist and the creator of the Newport ...
(Date:4/29/2016)... ... 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd annual ... skies, a light breeze and temperatures in the 60s. Over 400 runners, walkers and ... Walk and 1-mile walk were held to increase awareness about Lyme disease and ...
(Date:4/29/2016)... ... 29, 2016 , ... Mobility Designed is redefining mobility with their patent ... M+D Crutch evenly distributes body weight from the elbow to the forearm. In ... crutches than with other crutches. , Co-founders Max and Liliana Younger were inspired to ...
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
Breaking Medicine News(10 mins):